Cronos Australia Ltd. (AU:VIT) has released an update.
Vitura Health Limited has announced that its joint venture, Cortexa Pty. Ltd., has started batch production of GMP-grade MDMA capsules in Australia, marking a significant step in establishing a self-reliant local supply for clinical trials and authorized prescribers. By partnering with contract manufacturer Optima Ovest, Cortexa ensures secure domestic production and aims to lead the Australian market in psychedelic-assisted therapy. The company is also launching a medical education program to foster awareness and broaden market reach within the adult psychiatry community.
For further insights into AU:VIT stock, check out TipRanks’ Stock Analysis page.
